首页 文献索引 SCI期刊 AI助手
首页 正文

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025 Mar 27:jnumed.124.268901. doi: 10.2967/jnumed.124.268901 Q19.12025

Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study

在proPSMA研究中，[68Ga]Ga-PSMA-11正电子发射断层扫描/计算机断层扫描示低前列腺内摄取的活检证实的中间至高风险前列腺腺癌患者的患病率和中期转归分析 翻译改进

David C Chen  1  2, James P Buteau  1  3, Louise Emmett  4  5  6, Ramin Alipour  1  3, Felipe de Galiza Barbosa  7, Matthew J Roberts  8, Aoife McVey  9, Jonathan O'Brien  2, Sidney Levy  1  3, Roslyn J Francis  10, Nathan Lawrentschuk  2  3  11  12, Declan G Murphy  2  3, Michael S Hofman  13  3

作者单位 +展开

作者单位

  • 1 Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • 2 Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • 3 Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • 4 Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • 5 Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • 6 St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
  • 7 Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland.
  • 8 Department of Urology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
  • 9 Department of Radiology, University Hospital Geelong, Geelong, Victoria, Australia.
  • 10 Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
  • 11 Department of Urology, Royal Melbourne Hospital, Parkville, Victoria, Australia; and.
  • 12 EJ Whitten Foundation Prostate Cancer Research Centre at Epworth, Richmond, Victoria, Australia.
  • 13 Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; michael.hofman@petermac.org.

    • DOI: 10.2967/jnumed.124.268901 PMID: 40147846

    摘要 Ai翻译

    The current prevalence of low intraprostatic uptake for staging prostate-specific membrane antigen (PSMA) PET ranges between 4.4% and 17% in retrospective studies. We aimed to define the prevalence and describe the outcomes of patients with low intraprostatic uptake on PSMA PET/CT in the prospective proPSMA study. Methods: We identified patients with an SUVmax of 4 or less on PSMA PET/CT in the proPSMA study. Patients were followed up until 42 mo after ran... ...点击完成人机验证后继续浏览
    Copyright © Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 中文内容为AI机器翻译，仅供参考！

    相关内容

    期刊名：Journal of nuclear medicine

    缩写：J NUCL MED

    ISSN：0161-5505

    e-ISSN：1535-5667

    IF/分区：9.1/Q1

    文章目录 更多期刊信息

    全文链接
    官方链接
    PMC全文
    引文链接
    复制
    已复制！
    推荐内容
    Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study